119 related articles for article (PubMed ID: 18755121)
1. [Impact of clinical practice guides on the cost of caring for community acquired pneumonia].
Boada Senciales F; Moreno Arrebola E; Buñuel Alvarez JC; Vila Pablos C
An Pediatr (Barc); 2008 Aug; 69(2):154-8. PubMed ID: 18755121
[TBL] [Abstract][Full Text] [Related]
2. Direct costs in patients hospitalised with community-acquired pneumonia after non-response to outpatient treatment with macrolide antibacterials in the US.
Paladino JA; Adelman MH; Schentag JJ; Iannini PB
Pharmacoeconomics; 2007; 25(8):677-83. PubMed ID: 17640109
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with hospitalization costs for patients with community-acquired pneumonia.
Merchant S; Mullins CD; Shih YC
Clin Ther; 2003 Feb; 25(2):593-610. PubMed ID: 12749516
[TBL] [Abstract][Full Text] [Related]
4. Resource use and cost of care for patients hospitalised with community acquired pneumonia: impact of adherence to infectious diseases society of america guidelines.
Orrick JJ; Segal R; Johns TE; Russell W; Wang F; Yin DD
Pharmacoeconomics; 2004; 22(11):751-7. PubMed ID: 15250752
[TBL] [Abstract][Full Text] [Related]
5. Oral versus i.v. antibiotics for community-acquired pneumonia in children: a cost-minimisation analysis.
Lorgelly PK; Atkinson M; Lakhanpaul M; Smyth AR; Vyas H; Weston V; Stephenson T
Eur Respir J; 2010 Apr; 35(4):858-64. PubMed ID: 19717479
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacoeconomic estimation of cost of community acquired pneumonia therapy].
Kulidzhanov AIu; Sirotko II; Koriakin PM; Korchazhkin VS
Voen Med Zh; 2001 Jan; 322(1):50-2. PubMed ID: 11219929
[No Abstract] [Full Text] [Related]
7. Adherence to guidelines for community-acquired pneumonia: does it decrease cost of care?
Brown PD
Pharmacoeconomics; 2004; 22(7):413-20. PubMed ID: 15137880
[TBL] [Abstract][Full Text] [Related]
8. A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial.
Samsa GP; Matchar DB; Harnett J; Wilson J
Chest; 2005 Nov; 128(5):3246-54. PubMed ID: 16304269
[TBL] [Abstract][Full Text] [Related]
9. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
10. Impact of a guideline on management of children hospitalized with community-acquired pneumonia.
Newman RE; Hedican EB; Herigon JC; Williams DD; Williams AR; Newland JG
Pediatrics; 2012 Mar; 129(3):e597-604. PubMed ID: 22351891
[TBL] [Abstract][Full Text] [Related]
11. Influence of hospital guidelines on management of children hospitalized with pneumonia.
Neuman MI; Hall M; Hersh AL; Brogan TV; Parikh K; Newland JG; Blaschke AJ; Williams DJ; Grijalva CG; Tyler A; Shah SS
Pediatrics; 2012 Nov; 130(5):e823-30. PubMed ID: 23090342
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of adherence to treatment guidelines in nonintensive care pneumonia.
Menéndez R; Reyes S; Martínez R; de la Cuadra P; Manuel Vallés J; Vallterra J
Eur Respir J; 2007 Apr; 29(4):751-6. PubMed ID: 17005580
[TBL] [Abstract][Full Text] [Related]
13. Impact of guidelines on outcome: the evidence.
Martínez R; Reyes S; Lorenzo MJ; Menéndez R
Semin Respir Crit Care Med; 2009 Apr; 30(2):172-8. PubMed ID: 19296417
[TBL] [Abstract][Full Text] [Related]
14. Prospective, randomised study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalised patients with community-acquired pneumonia.
Falguera M; Ruiz-González A; Schoenenberger JA; Touzón C; Gázquez I; Galindo C; Porcel JM
Thorax; 2010 Feb; 65(2):101-6. PubMed ID: 19703825
[TBL] [Abstract][Full Text] [Related]
15. A population-based study of the costs of care for community-acquired pneumonia.
Bartolomé M; Almirall J; Morera J; Pera G; Ortún V; Bassa J; Bolíbar I; Balanzó X; Verdaguer A;
Eur Respir J; 2004 Apr; 23(4):610-6. PubMed ID: 15083763
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia.
Dresser LD; Niederman MS; Paladino JA
Chest; 2001 May; 119(5):1439-48. PubMed ID: 11348951
[TBL] [Abstract][Full Text] [Related]
17. Economic cost of community-acquired pneumonia in New Zealand adults.
Scott G; Scott H; Turley M; Baker M
N Z Med J; 2004 Jun; 117(1196):U933. PubMed ID: 15280937
[TBL] [Abstract][Full Text] [Related]
18. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance.
Kuti JL; Capitano B; Nicolau DP
Pharmacoeconomics; 2002; 20(8):513-28. PubMed ID: 12109917
[TBL] [Abstract][Full Text] [Related]
19. A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
Lloyd A; Holman A; Evers T
Curr Med Res Opin; 2008 May; 24(5):1279-84. PubMed ID: 18358083
[TBL] [Abstract][Full Text] [Related]
20. Implementing a standardized order set for community-acquired pneumonia: impact on mortality and cost.
Fleming NS; Ogola G; Ballard DJ
Jt Comm J Qual Patient Saf; 2009 Aug; 35(8):414-21. PubMed ID: 19719077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
